Phase II Study Evaluating the Efficacy and Safety of KX-826 in the Treatment of Chinese Male Androgenetic Alopecia
Condition: Androgenetic Alopecia (AGA) Interventions: Drug: KX-826-2.5 mg (0.25%)/60 mL BID; Drug: KX-826-5 mg (5%)/60 mL QD; Drug: KX-826-5 mg (5%)/60 mL BID; Other: Placebo Sponsor: Suzhou Kintor Pharmaceutical Inc, Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials